HIV Prevention Utilizing Long-acting Injectables-Reference-Cited by-同舟云学术

HIV Prevention Utilizing Long-acting Injectables

Published:2022 Issue:1 Volume:1 Page:31
ISSN:2755-113X
Container-title:Infectious Diseases
language:en
Short-container-title:

Author:

Egelund Eric F,Huston Jessica, , ,

Abstract

Pre-exposure prophylaxis (PrEP) is an essential component in ending the HIV pandemic. Unfortunately, PrEP uptake has not been optimal to date. This is due to various reasons, one of which is adherence. Long-acting injectables may help to overcome this barrier. This brief review discusses the long-acting injectables currently in use for PrEP (cabotegravir) and HIV treatment (cabotegravir and lenacapavir), as well as those currently undergoing clinical trials. Other promising agents are being studied, including islatravir and broadly neutralizing monoclonal antibodies. Furthermore, agents currently used for HIV treatment will likely be evaluated in preclinical and clinical studies for their use as PrEP agents.

Funder

This article is published under the Creative Commons Attribution Non-commercial License.

Publisher

Touch Medical Media, Ltd.

Reference51 articles.

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2022. Available at: www.unaids.org/en (accessed 21 September 2022).

2. Centers for Disease Control and Prevention. Ending the HIV epidemic in the U.S. (EHE). 2022. Available at: www.cdc.gov/endhiv/index.html (accessed 21 September 2022).

3. Chou R, Evans C, Hoverman A, et al. Preexposure prophylaxis for the prevention of HIV infection: Evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;321:2214–30.

4. Bavinton BR, Grulich AE. HIV pre-exposure prophylaxis: Scaling up for impact now and in the future. Lancet Public Health. 2021;6:e528–33.

5. Grulich AE, Bavinton BR. Scaling up preexposure prophylaxis to maximize HIV prevention impact. Curr Opin HIV AIDS. 2022;17:173–8.